Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 13  •  04:00PM ET
93.32
Dollar change
-0.99
Percentage change
-1.05
%
Index
S&P 500
P/E
7.16
EPS (ttm)
13.03
Insider Own
2.64%
Shs Outstand
352.90M
Perf Week
-1.46%
Market Cap
32.61B
Forward P/E
9.37
EPS next Y
9.96
Insider Trans
-3.11%
Shs Float
340.15M
Perf Month
-2.99%
Enterprise Value
-
PEG
3.42
EPS next Q
2.40
Inst Own
93.25%
Perf Quarter
-5.36%
Income
4.83B
P/S
1.70
EPS this Y
-5.81%
Inst Trans
-2.62%
Perf Half Y
3.93%
Sales
19.17B
P/B
1.41
EPS next Y
7.10%
ROA
7.39%
Perf YTD
-2.71%
Book/sh
66.19
P/C
-
EPS next 5Y
2.74%
ROE
21.31%
52W High
103.39 -9.74%
Perf Year
-0.11%
Cash/sh
-
P/FCF
5.56
EPS past 3/5Y
45.00% 28.39%
ROIC
18.76%
52W Low
82.44 13.19%
Perf 3Y
27.62%
EV/EBITDA
-
Sales past 3/5Y
26.93% 18.36%
Gross Margin
-
Volatility
1.71% 2.09%
Perf 5Y
145.84%
EV/Sales
-
EPS Y/Y TTM
32.96%
Oper. Margin
26.24%
ATR (14)
1.98
Perf 10Y
310.62%
Quick Ratio
-
Sales Y/Y TTM
8.66%
Profit Margin
25.21%
RSI (14)
41.92
Current Ratio
0.47
EPS Q/Q
95.22%
SMA20
-2.22%
Beta
0.35
Debt/Eq
0.11
Sales Q/Q
-5.61%
SMA50
-2.20%
Rel Volume
1.20
Prev Close
94.31
Employees
8000
LT Debt/Eq
0.07
SMA200
0.20%
Avg Volume
1.97M
Price
93.32
IPO
Sep 14, 1995
Option/Short
Yes / Yes
Trades
Volume
2,377,127
Change
-1.05%
Date Action Analyst Rating Change Price Target Change
Dec-16-25Initiated Mizuho Neutral $95
Nov-25-25Resumed RBC Capital Mkts Outperform $108
Oct-14-25Initiated Goldman Sell $88
Sep-16-25Initiated Wolfe Research Peer Perform
Aug-13-25Initiated Citigroup Buy $113
Aug-13-25Initiated Cantor Fitzgerald Neutral $98
Jul-09-25Downgrade Keefe Bruyette Outperform → Mkt Perform $101
Jun-10-25Downgrade Jefferies Buy → Hold $100
Sep-05-24Initiated Barclays Equal Weight $120
Aug-23-24Reiterated ROTH MKM Buy $110 → $125
Apr-29-26 12:30PM
08:30AM
Apr-28-26 04:15PM
04:01PM
Mar-17-26 08:03AM
12:11PM Loading…
Mar-10-26 12:11PM
Mar-06-26 11:51AM
Mar-05-26 08:30AM
Mar-03-26 05:24AM
Feb-27-26 09:00AM
Feb-24-26 08:49AM
Feb-19-26 11:18AM
Feb-18-26 09:29AM
Feb-12-26 11:24AM
11:01AM
08:51AM Loading…
08:51AM
Feb-11-26 01:26PM
Feb-10-26 04:03PM
03:49PM
11:15AM
11:14AM
Feb-09-26 06:30PM
05:45PM
04:58PM
04:25PM
10:50AM
Feb-08-26 07:38AM
04:22AM
Feb-05-26 08:30AM
Feb-04-26 05:02PM
12:34PM Loading…
12:34PM
10:03AM
10:00AM
09:15AM
08:55AM
Feb-03-26 10:31AM
Feb-02-26 10:00AM
Jan-29-26 06:00PM
09:35AM
Jan-28-26 08:55AM
Jan-26-26 10:50AM
09:25AM
Jan-23-26 09:20AM
Jan-22-26 10:21AM
08:30AM
Jan-20-26 06:15PM
Jan-16-26 09:37AM
Jan-13-26 06:00PM
08:55AM
08:13AM
Jan-12-26 12:10PM
08:55AM
Jan-09-26 09:30AM
Jan-08-26 04:11PM
Jan-07-26 06:00PM
09:37AM
Jan-02-26 06:15PM
Dec-26-25 08:48AM
Dec-19-25 02:52PM
Dec-18-25 08:30AM
Dec-09-25 11:39AM
Dec-04-25 02:15PM
07:34AM
Dec-02-25 09:52AM
Dec-01-25 08:30AM
Nov-27-25 09:40AM
Nov-26-25 11:30AM
Nov-25-25 04:02PM
Nov-21-25 10:51AM
Nov-18-25 08:49AM
Nov-17-25 09:03AM
Nov-14-25 08:30AM
Nov-13-25 09:15AM
07:17AM
Nov-11-25 10:20AM
09:40AM
Oct-30-25 03:14PM
12:07PM
01:30AM
Oct-28-25 01:29PM
01:30AM
Oct-27-25 06:00PM
05:20PM
04:21PM
04:05PM
09:19AM
Oct-24-25 09:16AM
Oct-23-25 10:47AM
10:42AM
10:20AM
10:19AM
Oct-22-25 10:00AM
09:15AM
Oct-21-25 12:00PM
09:40AM
Oct-20-25 10:00AM
09:53AM
08:50AM
Oct-17-25 11:06AM
10:19AM
Arch Capital Group Ltd. engages in the provision of property and casualty insurance and reinsurance lines. It operates through the following segments: Insurance, Reinsurance, Mortgage, Corporate, and Other. The Insurance segment consists of insurance underwriting units which offer specialty product lines like construction and national accounts, excess and surplus casualty, lenders products, professional lines, and programs. The Reinsurance segment is composed of reinsurance underwriting which offers specialty product lines such as casualty, marine and aviation, other specialty, property catastrophe, property excluding property catastrophe, and other. The Mortgage segment includes U.S. and international mortgage insurance and reinsurance operations as well as GSE credit risk sharing transactions. The Corporate segment represents net investment income, other income, corporate expense, interest expense, net realized gains and losses, and net impairment losses. The Other segment refers to Watford Re. which is a variable interest entity. The company was founded by Clements Robert in March 1995 and is headquartered in Hamilton, Bermuda.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Posner Brian SDirectorMay 11 '26Sale17.142,00034,2830May 12 04:32 PM
Houston Daniel JosephDirectorApr 30 '26Buy94.085,300498,6509,915May 04 05:10 PM
Posner Brian SDirectorMar 11 '26Sale17.113,00051,3452,000Mar 12 04:29 PM
Gansberg DavidPresident, Arch Capital GroupMar 10 '26Option Exercise18.9010,770203,553342,466Mar 12 04:29 PM
Gansberg DavidPresident, Arch Capital GroupMar 10 '26Sale96.375,907569,266336,559Mar 12 04:29 PM
Papadopoulo NicolasCEOMar 10 '26Option Exercise18.9021,930414,477893,524Mar 12 04:29 PM
Papadopoulo NicolasCEOMar 10 '26Sale96.3121,9302,112,063871,594Mar 12 04:29 PM
Papadopoulo NicolasOfficerMar 10 '26Proposed Sale96.3121,9302,112,063Mar 10 04:23 PM
Gansberg DavidOfficerMar 10 '26Proposed Sale96.375,907569,266Mar 10 04:22 PM
Rajeh MaamounPresident, Arch Capital GroupFeb 11 '26Option Exercise27.1247,4301,286,086481,019Feb 13 04:31 PM
Rajeh MaamounPresident, Arch Capital GroupFeb 11 '26Sale96.1247,4304,558,858433,589Feb 13 04:31 PM
Rajeh MaamounOfficerFeb 11 '26Proposed Sale96.1247,4304,558,859Feb 11 04:10 PM
PASQUESI JOHN MCHAIRDec 12 '25Sale93.90203,86619,142,047351,356Dec 16 05:32 PM
PASQUESI JOHN MCHAIRDec 15 '25Sale94.178,800828,684289,556Dec 16 05:32 PM
PASQUESI JOHN MDirectorDec 15 '25Proposed Sale94.178,800828,683Dec 15 04:53 PM
John Murray PasquesiDirectorDec 12 '25Proposed Sale93.8128,8662,707,802Dec 12 05:11 PM
PASQUESI JOHN MDirectorDec 12 '25Proposed Sale93.91175,00016,434,138Dec 12 05:09 PM
Morin FrancoisEVP AND CFONov 28 '25Sale94.628,000756,996266,681Dec 02 04:59 PM
Morin FrancoisOfficerNov 28 '25Proposed Sale94.628,000756,996Nov 28 01:48 PM
Rajeh MaamounPRESIDENT, ARCH CAPITAL GROUPAug 22 '25Sale94.1510,000941,464433,589Aug 25 07:08 PM
Rajeh MaamounOfficerAug 22 '25Proposed Sale94.1510,000941,464Aug 22 04:23 PM
Posner Brian SDirectorAug 01 '25Buy17.341,00017,3385,000Aug 04 04:23 PM
Morin FrancoisEVP AND CFOMay 16 '25Option Exercise18.9012,630238,707287,311May 20 04:41 PM
Morin FrancoisEVP AND CFOMay 16 '25Sale94.5812,6301,194,576274,681May 20 04:41 PM
Morin FrancoisOfficerMay 16 '25Proposed Sale94.5812,6301,194,575May 16 05:16 PM
Last Close
May 13  •  04:00PM ET
18.44
Dollar change
+0.07
Percentage change
0.38
%
DYN Dyne Therapeutics Inc daily Stock Chart
Index
RUT
P/E
-
EPS (ttm)
-3.23
Insider Own
21.68%
Shs Outstand
165.20M
Perf Week
-2.12%
Market Cap
3.05B
Forward P/E
-
EPS next Y
-2.96
Insider Trans
-7.31%
Shs Float
129.40M
Perf Month
-6.92%
Enterprise Value
2.25B
PEG
-
EPS next Q
-0.74
Inst Own
91.45%
Perf Quarter
10.55%
Income
-451.71M
P/S
-
EPS this Y
11.76%
Inst Trans
7.33%
Perf Half Y
-0.38%
Sales
0.00M
P/B
3.52
EPS next Y
3.21%
ROA
-50.16%
Perf YTD
-5.73%
Book/sh
5.24
P/C
3.13
EPS next 5Y
14.35%
ROE
-58.89%
52W High
25.00 -26.24%
Perf Year
52.40%
Cash/sh
5.88
P/FCF
-
EPS past 3/5Y
-2.41% 3.39%
ROIC
-43.91%
52W Low
8.06 128.78%
Perf 3Y
37.30%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
5.23% 5.41%
Perf 5Y
8.60%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
10.17%
Oper. Margin
-
ATR (14)
1.00
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
19.92
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
51.36
Dividend Gr. 3/5Y
- -
Current Ratio
19.92
EPS Q/Q
30.23%
SMA20
-0.15%
Beta
1.08
Payout
-
Debt/Eq
0.20
Sales Q/Q
-
SMA50
1.01%
Rel Volume
0.48
Prev Close
18.37
Employees
258
LT Debt/Eq
0.19
SMA200
9.07%
Avg Volume
2.05M
Price
18.44
IPO
Sep 17, 2020
Option/Short
Yes / Yes
Trades
Volume
979,944
Change
0.38%
Date Action Analyst Rating Change Price Target Change
Dec-10-25Upgrade Oppenheimer Perform → Outperform $40
Oct-10-25Downgrade Oppenheimer Outperform → Perform
Aug-25-25Upgrade Raymond James Outperform → Strong Buy $35
Jun-24-25Initiated Bernstein Mkt Perform $13
Jun-11-25Resumed Raymond James Outperform $37
Jun-02-25Resumed Oppenheimer Outperform $34
May-29-25Initiated Evercore ISI Outperform $46
Mar-12-25Initiated BMO Capital Markets Outperform $50
Mar-07-25Initiated Scotiabank Sector Outperform $50
Dec-13-24Initiated Robert W. Baird Outperform $46
Today 07:30AM
May-11-26 07:55AM
07:30AM
Apr-27-26 04:34PM
Apr-23-26 04:05PM
07:30AM Loading…
Apr-01-26 07:30AM
Mar-10-26 09:47PM
Mar-08-26 06:01PM
06:00PM
Mar-02-26 07:30AM
Feb-26-26 05:52AM
Feb-25-26 07:30AM
Feb-22-26 04:00PM
Feb-18-26 07:38PM
Feb-16-26 12:23PM
09:16AM Loading…
Jan-27-26 09:16AM
Jan-20-26 07:30AM
Jan-15-26 11:35AM
Jan-12-26 12:00PM
Jan-07-26 07:30AM
Dec-23-25 07:30AM
Dec-22-25 06:50AM
Dec-11-25 04:05PM
07:44AM
Dec-10-25 06:20PM
09:40AM
Dec-09-25 09:42PM
06:42PM
04:54PM
02:22PM
01:34PM Loading…
01:34PM
Dec-08-25 04:02PM
03:07PM
06:30AM
05:32AM
Dec-07-25 11:00AM
Nov-30-25 12:26AM
Nov-21-25 03:43PM
Nov-05-25 04:10PM
Nov-03-25 07:30AM
Oct-28-25 05:24AM
Oct-27-25 06:17PM
04:54PM
12:07PM
05:26AM
04:39AM
Oct-16-25 04:33PM
Oct-06-25 06:01PM
Oct-04-25 04:54PM
Oct-02-25 04:05PM
Sep-29-25 08:35AM
Sep-10-25 12:20AM
Aug-27-25 07:30AM
Aug-20-25 12:13AM
Aug-17-25 11:41PM
Aug-06-25 12:00PM
Aug-04-25 07:30AM
Jul-31-25 09:55AM
Jul-28-25 04:10PM
Jul-16-25 07:00AM
Jul-11-25 11:27AM
Jul-02-25 04:01PM
Jun-30-25 09:45PM
04:05PM
04:01PM
Jun-24-25 12:46PM
Jun-18-25 09:45AM
Jun-17-25 07:00AM
Jun-16-25 04:05PM
Jun-05-25 07:30AM
May-08-25 07:30AM
Apr-25-25 05:05AM
Apr-24-25 07:30AM
Apr-21-25 04:09PM
Apr-15-25 07:30AM
Apr-14-25 04:30PM
Apr-01-25 11:50AM
Mar-30-25 03:50AM
Mar-28-25 09:00AM
Mar-20-25 04:30PM
04:19PM
04:10PM
Mar-16-25 07:00PM
Mar-12-25 03:05PM
01:12PM
Mar-11-25 07:30AM
Feb-27-25 07:30AM
Feb-14-25 04:05PM
Feb-13-25 09:35AM
Feb-06-25 09:39AM
Feb-03-25 07:30AM
Jan-28-25 09:35AM
Jan-21-25 07:30AM
Jan-10-25 06:30AM
Jan-09-25 07:30AM
Jan-08-25 04:05PM
Nov-22-24 06:43AM
Nov-12-24 07:30AM
Nov-07-24 04:15PM
Oct-09-24 07:30AM
Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cox JohnOfficerMay 13 '26Proposed Sale18.363,31160,805May 13 04:57 PM
Lucera ErickOfficerMay 13 '26Proposed Sale18.361,44826,592May 13 04:55 PM
Rhodes Jason PDirectorMay 06 '26Sale18.1883,2191,512,9217,962May 06 05:09 PM
Rhodes Jason PDirectorMay 04 '26Sale18.0011,904214,2728,450May 06 05:09 PM
Rhodes Jason PDirectorMay 05 '26Sale18.0311,600209,1488,390May 06 05:09 PM
Atlas Venture Fund XI, LPShareholderMay 06 '26Proposed Sale17.4743,621762,059May 06 04:43 PM
Atlas Venture Opportunity FundShareholderMay 06 '26Proposed Sale17.4721,926383,047May 06 04:43 PM
Atlas Venture Associates XI, LShareholderMay 06 '26Proposed Sale17.474287,477May 06 04:42 PM
Atlas Venture Opportunity FundShareholderMay 06 '26Proposed Sale17.4717,244301,253May 06 04:42 PM
Atlas Venture Fund XI, LPShareholderMay 05 '26Proposed Sale17.716,081107,695May 05 04:39 PM
Atlas Venture Opportunity FundShareholderMay 05 '26Proposed Sale17.713,05654,122May 05 04:37 PM
Atlas Venture Associates XI, LShareholderMay 05 '26Proposed Sale17.71601,063May 05 04:36 PM
Atlas Venture Opportunity FundShareholderMay 05 '26Proposed Sale17.712,40342,557May 05 04:36 PM
Atlas Venture Opportunity FundShareholderMay 04 '26Proposed Sale17.392,46642,884May 04 05:00 PM
Atlas Venture Fund XI, LPShareholderMay 04 '26Proposed Sale17.396,241108,531May 04 04:59 PM
Atlas Venture Opportunity FundShareholderMay 04 '26Proposed Sale17.393,13654,535May 04 04:59 PM
Atlas Venture Associates XI, LShareholderApr 29 '26Proposed Sale17.39611,061May 04 04:59 PM
Rhodes Jason PDirectorApr 28 '26Sale18.38227,3374,178,5168,511Apr 30 05:22 PM
Atlas Venture Opportunity FundShareholderApr 28 '26Proposed Sale18.0447,103849,738Apr 28 04:44 PM
Atlas Venture Fund XI, LPShareholderApr 28 '26Proposed Sale18.04119,1672,149,773Apr 28 04:43 PM
Atlas Venture Opportunity FundShareholderApr 28 '26Proposed Sale18.0459,8361,079,441Apr 28 04:43 PM
Atlas Venture Associates XI, LShareholderApr 28 '26Proposed Sale18.041,17121,125Apr 28 04:42 PM
Rhodes Jason PDirectorApr 27 '26Sale18.15173,4933,148,8989,682Apr 27 06:15 PM
Rhodes Jason PDirectorApr 24 '26Sale18.48137,9482,549,27910,576Apr 27 06:15 PM
Rhodes Jason PDirectorApr 23 '26Sale19.1973,1081,402,94311,286Apr 27 06:15 PM
Atlas Venture Opportunity FundShareholderApr 27 '26Proposed Sale18.2645,709834,646Apr 27 04:49 PM
Atlas Venture Opportunity FundShareholderApr 27 '26Proposed Sale18.2635,947656,392Apr 27 04:48 PM
Atlas Venture Fund XI, LPShareholderApr 27 '26Proposed Sale18.2690,9431,660,619Apr 27 04:48 PM
Atlas Venture Associates XI, LShareholderApr 27 '26Proposed Sale18.2689416,324Apr 27 04:48 PM
Atlas Venture Opportunity FundShareholderApr 24 '26Proposed Sale18.9028,583540,219Apr 24 04:47 PM
Atlas Venture Opportunity FundShareholderApr 24 '26Proposed Sale18.9036,345686,920Apr 24 04:46 PM
Atlas Venture Fund XI, LPShareholderApr 24 '26Proposed Sale18.9072,3101,366,659Apr 24 04:46 PM
Atlas Venture Associates XI, LShareholderApr 24 '26Proposed Sale18.9071013,419Apr 24 04:45 PM
Atlas Venture Opportunity FundShareholderApr 23 '26Proposed Sale19.6715,148297,961Apr 23 04:46 PM
Atlas Venture Opportunity FundShareholderApr 23 '26Proposed Sale19.6719,261378,864Apr 23 04:45 PM
Atlas Venture Fund XI, LPShareholderApr 23 '26Proposed Sale19.6738,322753,794Apr 23 04:45 PM
Atlas Venture Associates XI, LShareholderApr 23 '26Proposed Sale19.673777,416Apr 23 04:45 PM
Kersten DirkDirectorApr 21 '26Sale20.018,300166,1204,199,225Apr 23 04:15 PM
Kersten DirkDirectorApr 22 '26Sale20.002,65253,0494,196,573Apr 23 04:15 PM
Rhodes Jason PDirectorApr 22 '26Sale19.68287,9565,666,97411,663Apr 22 06:27 PM
Rhodes Jason PDirectorApr 20 '26Sale20.06272,0495,457,30314,561Apr 22 06:27 PM
Rhodes Jason PDirectorApr 21 '26Sale19.52274,2975,353,11113,148Apr 22 06:27 PM
Atlas Venture Opportunity FundShareholderApr 22 '26Proposed Sale19.2159,6631,146,126Apr 22 04:54 PM
Atlas Venture Opportunity FundShareholderApr 22 '26Proposed Sale19.2175,8661,457,386Apr 22 04:53 PM
Atlas Venture Fund XI, LPShareholderApr 22 '26Proposed Sale19.21150,9422,899,596Apr 22 04:53 PM
Atlas Venture Associates XI, LShareholderApr 22 '26Proposed Sale19.211,48528,527Apr 22 04:52 PM
Atlas Venture Fund XI, LPShareholderApr 21 '26Proposed Sale20.02143,7492,877,855Apr 21 04:54 PM
Atlas Venture Opportunity FundShareholderApr 21 '26Proposed Sale20.0256,8201,137,536Apr 21 04:53 PM
Atlas Venture Opportunity FundShareholderApr 21 '26Proposed Sale20.0272,3151,447,746Apr 21 04:53 PM
Atlas Venture Associates XI, LShareholderApr 21 '26Proposed Sale20.021,41328,288Apr 21 04:53 PM
Kersten DirkDirectorApr 17 '26Sale20.29211,9744,301,2924,332,799Apr 21 04:15 PM
Kersten DirkDirectorApr 20 '26Sale20.07125,2742,513,8984,207,525Apr 21 04:15 PM
Atlas Venture Fund XI, LPShareholderApr 20 '26Proposed Sale20.41142,5712,909,874Apr 20 04:44 PM
Atlas Venture Opportunity FundShareholderApr 20 '26Proposed Sale20.4156,3551,150,206Apr 20 04:44 PM
Atlas Venture Opportunity FundShareholderApr 20 '26Proposed Sale20.4171,7221,463,846Apr 20 04:44 PM
Atlas Venture Associates XI, LShareholderApr 20 '26Proposed Sale20.411,40128,594Apr 20 04:43 PM
Kersten DirkDirectorApr 15 '26Sale20.2781,8401,659,0444,562,546Apr 17 04:05 PM
Kersten DirkDirectorApr 16 '26Sale20.7117,773368,1144,544,773Apr 17 04:05 PM
Lucera ErickChief Financial OfficerApr 01 '26Sale18.645,727106,751125,373Apr 03 04:10 PM
Posner Brian SDirectorMar 30 '26Buy17.082,00034,16015,500Apr 01 04:27 PM
Lucera ErickOfficerApr 01 '26Proposed Sale18.645,727106,758Apr 01 04:06 PM
Posner Brian SDirectorMar 11 '26Buy19.352,00038,70013,500Mar 13 04:46 PM
Kersten DirkDirectorMar 11 '26Sale19.52129,6722,530,5624,644,386Mar 13 04:35 PM
Kersten DirkDirectorMar 10 '26Sale19.57511,09810,000,3274,774,058Mar 11 05:27 PM
Kersten DirkDirectorMar 09 '26Sale17.72177,6903,148,9875,285,156Mar 11 05:27 PM
ForDyne B.V.AffiliateMar 11 '26Proposed Sale19.75807,29515,944,076Mar 11 04:05 PM
Posner Brian SDirectorMar 06 '26Buy15.063,00045,18011,500Mar 10 05:33 PM
ForDyne B.V.AffiliateMar 09 '26Proposed Sale17.72807,29514,306,720Mar 09 04:09 PM
Friedl-Naderer JohannaChief Commercial OfficerMar 05 '26Sale14.901482,205154,581Mar 06 04:10 PM
Kerr DouglasChief Medical OfficerMar 05 '26Sale14.9090413,470171,606Mar 06 04:09 PM
Cox JohnCEO & PresidentMar 05 '26Sale14.902,73240,707374,145Mar 06 04:08 PM
Cox JohnOfficerMar 05 '26Proposed Sale14.902,73240,707Mar 05 04:06 PM
Kerr DouglasOfficerDec 05 '25Proposed Sale20.7288018,231Dec 05 04:56 PM
Cox JohnOfficerDec 05 '25Proposed Sale20.722,66255,150Dec 05 04:55 PM
Cox JohnCEO & PresidentDec 05 '25Sale20.722,66255,157196,877Dec 05 04:11 PM
Kerr DouglasChief Medical OfficerDec 05 '25Sale20.7288018,23487,510Dec 05 04:09 PM
Friedl-Naderer JohannaChief Commercial OfficerDec 05 '25Sale20.721442,98494,729Dec 05 04:08 PM
Cox JohnCEO & PresidentSep 05 '25Sale13.412,64035,402199,539Sep 09 04:31 PM
Friedl-Naderer JohannaChief Commercial OfficerSep 04 '25Sale13.2789411,86395,017Sep 08 04:06 PM
Friedl-Naderer JohannaChief Commercial OfficerSep 05 '25Sale13.411441,93194,873Sep 08 04:06 PM
Kerr DouglasChief Medical OfficerSep 04 '25Sale13.273,55247,13589,263Sep 08 04:03 PM
Kerr DouglasChief Medical OfficerSep 05 '25Sale13.4187311,70788,390Sep 08 04:03 PM
Cox JohnOfficerSep 05 '25Proposed Sale13.412,64035,404Sep 05 04:14 PM
Kerr DouglasOfficerSep 04 '25Proposed Sale13.274,55260,402Sep 04 04:45 PM
Cox JohnCEO & PresidentJul 14 '25Buy9.11100,000911,000242,179Jul 15 05:11 PM
Scalzo Richard WilliamOfficerJun 11 '25Proposed Sale14.751,33019,619Jun 11 04:30 PM
Beskrovnaya OxanaOfficerJun 11 '25Proposed Sale14.752,13231,449Jun 11 04:29 PM
Cox JohnCEO & PresidentJun 05 '25Sale13.354,06054,201142,179Jun 06 04:07 PM
Kerr DouglasChief Medical OfficerJun 05 '25Sale13.351,34217,91692,815Jun 06 04:05 PM
Friedl-Naderer JohannaChief Commercial OfficerJun 05 '25Sale13.351461,94995,911Jun 06 04:03 PM
Kerr DouglasOfficerJun 05 '25Proposed Sale13.351,34217,911Jun 05 04:13 PM
Cox JohnOfficerJun 05 '25Proposed Sale13.354,06054,186Jun 05 04:11 PM
Scalzo Richard WilliamOfficerJun 05 '25Proposed Sale13.3591412,198Jun 05 04:09 PM
Beskrovnaya OxanaOfficerJun 05 '25Proposed Sale13.351,09314,587Jun 05 04:07 PM
Scalzo Richard WilliamOfficerMay 16 '25Proposed Sale11.822,47929,313May 16 04:10 PM
Beskrovnaya OxanaOfficerMay 16 '25Proposed Sale11.822,58930,614May 16 04:09 PM